Anti CD19 CAR-T Cell Therapy Can Clear Minimal Residual Disease in Bone Marrow of Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphomas

Authors

Armaan Dhaliwal MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

11-2022

Volume

140

Issue

1

Published In/Presented At

10.1182/blood-2022-170620

Disciplines

Medicine and Health Sciences

Department(s)

Fellows and Residents

Document Type

Article